168 related articles for article (PubMed ID: 35708082)
21. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
Xiao L; Liu Y; Chen H; Shen L
Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
[TBL] [Abstract][Full Text] [Related]
22. A positive feedback loop links opposing functions of P-TEFb/Cdk9 and histone H2B ubiquitylation to regulate transcript elongation in fission yeast.
Sansó M; Lee KM; Viladevall L; Jacques PÉ; Pagé V; Nagy S; Racine A; St Amour CV; Zhang C; Shokat KM; Schwer B; Robert F; Fisher RP; Tanny JC
PLoS Genet; 2012; 8(8):e1002822. PubMed ID: 22876190
[TBL] [Abstract][Full Text] [Related]
23. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases.
Romano G; Giordano A
Cell Cycle; 2008 Dec; 7(23):3664-8. PubMed ID: 19029809
[TBL] [Abstract][Full Text] [Related]
24. Transcription factor IIS cooperates with the E3 ligase UBR5 to ubiquitinate the CDK9 subunit of the positive transcription elongation factor B.
Cojocaru M; Bouchard A; Cloutier P; Cooper JJ; Varzavand K; Price DH; Coulombe B
J Biol Chem; 2011 Feb; 286(7):5012-22. PubMed ID: 21127351
[TBL] [Abstract][Full Text] [Related]
25. A patent review of selective CDK9 inhibitors in treating cancer.
Wu T; Wu X; Xu Y; Chen R; Wang J; Li Z; Bian J
Expert Opin Ther Pat; 2023 Apr; 33(4):309-322. PubMed ID: 37128897
[TBL] [Abstract][Full Text] [Related]
26. Selective control of gene expression by CDK9 in human cells.
Garriga J; Xie H; Obradovic Z; Graña X
J Cell Physiol; 2010 Jan; 222(1):200-8. PubMed ID: 19780058
[TBL] [Abstract][Full Text] [Related]
27. CDK9 inhibition strategy defines distinct sets of target genes.
Garriga J; Graña X
BMC Res Notes; 2014 May; 7():301. PubMed ID: 24886624
[TBL] [Abstract][Full Text] [Related]
28. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.
Zhang H; Pandey S; Travers M; Sun H; Morton G; Madzo J; Chung W; Khowsathit J; Perez-Leal O; Barrero CA; Merali C; Okamoto Y; Sato T; Pan J; Garriga J; Bhanu NV; Simithy J; Patel B; Huang J; Raynal NJ; Garcia BA; Jacobson MA; Kadoch C; Merali S; Zhang Y; Childers W; Abou-Gharbia M; Karanicolas J; Baylin SB; Zahnow CA; Jelinek J; Graña X; Issa JJ
Cell; 2018 Nov; 175(5):1244-1258.e26. PubMed ID: 30454645
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
[TBL] [Abstract][Full Text] [Related]
30. Separate domains of fission yeast Cdk9 (P-TEFb) are required for capping enzyme recruitment and primed (Ser7-phosphorylated) Rpb1 carboxyl-terminal domain substrate recognition.
St Amour CV; Sansó M; Bösken CA; Lee KM; Larochelle S; Zhang C; Shokat KM; Geyer M; Fisher RP
Mol Cell Biol; 2012 Jul; 32(13):2372-83. PubMed ID: 22508988
[TBL] [Abstract][Full Text] [Related]
31. CDK9-dependent RNA polymerase II pausing controls transcription initiation.
Gressel S; Schwalb B; Decker TM; Qin W; Leonhardt H; Eick D; Cramer P
Elife; 2017 Oct; 6():. PubMed ID: 28994650
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
33. Cyclins that don't cycle--cyclin T/cyclin-dependent kinase-9 determines cardiac muscle cell size.
Sano M; Schneider MD
Cell Cycle; 2003; 2(2):99-104. PubMed ID: 12695656
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4(+) T lymphocytes.
Ramakrishnan R; Dow EC; Rice AP
J Leukoc Biol; 2009 Dec; 86(6):1345-50. PubMed ID: 19741158
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma.
Shao YY; Hsu HW; Wo RR; Wang HY; Cheng AL; Hsu CH
Oncology; 2022; 100(11):602-611. PubMed ID: 36103810
[TBL] [Abstract][Full Text] [Related]
36. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
38. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.
Lu H; Xue Y; Yu GK; Arias C; Lin J; Fong S; Faure M; Weisburd B; Ji X; Mercier A; Sutton J; Luo K; Gao Z; Zhou Q
Elife; 2015 Jun; 4():e06535. PubMed ID: 26083714
[TBL] [Abstract][Full Text] [Related]
39. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.
Polier G; Ding J; Konkimalla BV; Eick D; Ribeiro N; Köhler R; Giaisi M; Efferth T; Desaubry L; Krammer PH; Li-Weber M
Cell Death Dis; 2011 Jul; 2(7):e182. PubMed ID: 21776020
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Shan B; Zhuo Y; Chin D; Morris CA; Morris GF; Lasky JA
J Biol Chem; 2005 Jan; 280(2):1103-11. PubMed ID: 15528190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
